Abstract
Background: Background: Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis present in tropical or subtropical regions, caused by the traumatic inoculation of various species of melanized fungi, the most common being Fonsecaea pedrosoi and Cladophialophora carrionii. It is characterized in early stages by erythematous macules or papules with a verrucous or hyperkeratotic appearance, which progress to nodular, verrucous, tumoral, plaque, or scar-like morphologies.
Objective: to describe a classic presentation and conduct a narrative review of CBM with a prolonged evolution time and multifocal extension.
Case report: 69-year-old man, a farmer by occupation, with a history of hypertension, heart failure with preserved ejection fraction, colonic diverticulosis, and umbilical hernia. He was admitted to the emergency department with a one-day history of dyspnea, chills, asthenia, adynamia, and fever, consistent with exacerbated chronic lung disease and pneumonia. Given a 10-year history of progressive growth of painless and pruritic papular skin lesions that spread with various presentations to other areas of the body, a potassium hydroxide (KOH) test was performed, revealing mycotic structures and the presence of yeasts. Meanwhile, the skin biopsy reported findings of pseudoepitheliomatous hyperplasia and intraepidermal abscesses with Medlar bodies, pathognomonic of CBM.
Conclusion: The case highlights the importance of an accurate diagnosis of an overlooked tropical disease and the establishment of personalized antifungal treatment, as well as the need for long-term monitoring due to the chronic nature of the pathology and its marked resistance to treatment.
Keywords: Chromoblastomycosis; Neglected diseases; Dermatomycoses.
References
1. Shenoy MM, Girisha BS, Krishna S. Chromoblastomycosis: A Case Series and Literature Review. Indian Dermatol Online J 2023; 14 (5): 665-669. doi: 10.4103/idoj.idoj_292_23.
2. Santos DWCL, de Azevedo C de MP e S, Vicente VA, et al. The global burden of chromoblastomycosis. PLoS Negl Trop Dis 2021; 15 (8): e0009611. doi: 10.1371/journal.pntd.0009611
3. Chromoblastomycosis. World Health Organization 2023. https://www.who.int/es/news-room/fact-sheets/detail/chromoblastomycosis
4. Queiroz-Telles F, de Hoog S, Santos DWCL, et al. Chromoblastomycosis. Clin Microbiol Rev 2017; 30 (1): 233-276. doi: 10.1128/CMR.00032-16
5. Suárez-Ospino N, Salas-Hine I, Quiñonez-Rodríguez A, Ochoa-Díaz A, et al. Cromoblastomicosis verrugosa-cicatricial multifocal: una entidad desatendida en Colombia. Rev Chile Infectol 2023; 40 (3): 298-302. doi: 10.4067/s0716-10182023000300298
6. García-Gómez D, López-Pérez M, Adjudah-Truffín C. Diagnóstico microbiológico en un paciente con cromomicosis. Medicentro Electrónica 2020; 691-698. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30432020000300691&lng=es.
7. Barbosa LSP, Souza YRC, Sasaki CS, Santos DWD, Rossato L. Chromoblastomycosis in Brazil: A review of 450 published cases. Rev Soc Bras Med Trop 2024; 57: e00205-2024. doi: 10.1590/0037-8682-0132-2024.
8. Jahr C, Peruilh L, Jiménez M, Bobadilla F, et al. Cromoblastomicosis. Primer caso alóctono tratado en Chile. Rev Chile Infectol 2022; 39 (3): 349-353. doi: 10.4067/s0716-10182022000200349
9. Lau WC, Damji Y, Orlowski GM. An unusually subtle presentation of chromoblastomycosis. JAAD Case Rep 2023; 40: 11-13. doi: 10.1016/j.jdcr.2023.07.029
10. Campos-Macias P, Arenas R, Aquino CJ, et al. Chromoblastomycosis caused by Fonsecaea monophora in Mexico. J Med Mycol 2021; 31 (2): 101114. doi: 10.1016/j.mycmed.2021.101114
11. Smith DJ, Queiroz-Telles F, Rabenja FR, et al. A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group. PLoS Negl Trop Dis 2024; 18 (10): e0012562. doi: 10.1371/journal.pntd.0012562
12. Informe Mundial Sobre Las Enfermedades Tropicales Desatendidas 2024. World Health Organization 2024. doi: 10.2471/B09064
13. Kurien G, Sugumar K, Sathe NC, Chandran V. Chromoblastomycosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing 2024; https://www.ncbi.nlm.nih.gov/books/NBK470253/
14. Oprea Y, Stringer T, Mattis D, Amin B, et al. Chromoblastomycosis Caused by Fonsecaea monophora Mimicking Lichen Planus. Cureus 2024; 16 (2): e53863. doi:10.7759/cureus.53863
15. Cinotti E, Cioppa V, Tognetti L, et al. Super-High Magnification Dermoscopy in 190 Clinically Atypical Pigmented Lesions. Diagnostics (Basel) 2023; 13 (13): 2238. doi: 10.3390/diagnostics13132238
16. Cortonesi G, Cosetti D, Suppa M, Habougit C, et al. Non-invasive Imaging Techniques for the Diagnosis of Chromoblastomycosis. Dermatol Pract Concept 2024; 14 (4): e2024236. doi: 10.5826/dpc.1404a236
17. Falgout L, Hilton D. Clinical presentation and management of chromoblastomycosis: A case report and review. Med Mycol Case Rep 2023; 41: 8-10. doi: 10.1016/j.mmcr.2023.05.004
18. Khodeir J, Ohanian P, Megarbane HAR. Triple therapy approach for treating chromoblastomycosis in a Lebanese patient. Clin Case Rep 2024; 12 (10). doi: 10.1002/ccr3.9392
19.Zheng J, Liu S, Xie Z, et al. Successful management of chromoblastomycosis utilizing conventional antifungal agents and imiquimod therapy. Ann Clin Microbiol Antimicrob 2024; 23 (1): 57. doi: 10.1186/s12941-024-00718-y
20. Martinelli MB, Cockerell CJ, Cohen PR. Treatment-Resistant Chromoblastomycosis Successfully Managed With Surgical Excision. Cureus 2024; 16 (11): e73619. doi: 10.7759/cureus.73619

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México
